palmitoylethanolamide.com.au
Menu
Home › Research › Wenju 2022

Effects of Gabexate Mesylate on the Gut Microbiota and Metabolomics in Rats with Sepsis

Wenju Sun, Yuqing Cui, Xiaojuan Zhang, Yuze Wang, Zihao Zhang, Xianfei Ding, Huoyan Liang, Dong Wang, Yali Sun, Shaohua Liu, Xiaoguang Duan, Yibin Lu, Tongwen Sun. J Inflamm Res. 2022 Dec 5:15:6581-6594.

Laboratory studyOther animals

Design
Laboratory study
Subjects
60 SD rats in sham, caecal ligation and puncture (CLP), and gabexate mesylate groups
Dose used in the study
No palmitoylethanolamide was given; gabexate mesylate by injection, dose not stated in the abstract
Duration
24 hours after the procedure
What was measured
Mortality, gut microbiota sequencing and faecal metabolomics, and lung histology.

What the authors reported

This study found:

  • Gabexate mesylate raised Pygmaiobacter, Lactobacillus and Erysipelotrichaceae UCG-003 and lowered Escherichia-Shigella and Akkermansia.
  • Palmitoylethanolamide, deoxycholic acid and chenodeoxycholic acid correlated with the shifted genera (P < 0.05).
  • Mortality was 10/20 in the CLP group versus 0/20 in sham and 4/20 in the treated group.

Limits of this study

A rat sepsis model; it cannot show effect in people or animals treated in practice. PEA was one metabolite that changed, not a treatment. The authors declare no conflicts of interest.

Source

PubMed 36506782 · doi:10.2147/JIR.S392060

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.